GLPBio

SOR-C13

Catalog No.: GC74344Purity:>98.00%
COASDSData Sheet
SOR-C13 is a transient receptor potential vanilloid subtype 6 (TRPV6) polypeptide antagonist (IC50=14nM).

Products are for research use only. Not for human use. We do not sell to patients.

SOR-C13
Cas No.: 1187852-48-7
1 mgIn Stock
$56.00
1
5 mgIn Stock
$144.00
1
10 mgIn Stock
$224.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

SOR-C13 is a transient receptor potential vanilloid subtype 6 (TRPV6) polypeptide antagonist (IC50=14nM). SOR-C13 inhibits TRPV6 calcium channel-mediated Ca2+ influx to reduce calcium signaling and proliferation in tumor cells. SOR-C13 suppresses epithelial tumor growth in the ovary, breast, prostate and pancreas through TRPV6-targeted binding. SOR-C13 can be used in studies on TRPV6-overexpressing solid tumors and tumor-targeted delivery[1-4].

In vitro, 25-83.5μM SOR-C13 was applied to TRPV6-transfected HEK-293 cells for 600ms. SOR-C13 reduced TRPV6 current amplitude[5]. Caco-2 cells were pretreated with 10μM SOR-C13 for 30 minutes, then treated with 200μM lithocholic acid for 24 hours. SOR-C13 blocked lithocholic acid-induced inhibition of DSG2 protein expression and inhibited lithocholic acid-induced decrease in transepithelial electrical resistance TEER[6].

In vivo, NOD/SCID mice bearing SKOV-3 cell xenografts received intraperitoneal injections of 400-800mg/kg SOR-C13 daily for 12 days. SOR-C13 inhibited tumor growth[7].

References:
[1] Fu S, Hirte H, Welch S, et al. First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):324-333.
[2] Pennington MW, Czerwinski A, Norton RS. Peptide therapeutics from venom: Current status and potential. Bioorg Med Chem. 2018;26(10):2738-2758.
[3] Bordon KCF, Cologna CT, Fornari-Baldo EC, et al. From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery. Front Pharmacol. 2020 Jul 24;11:1132.
[4] Neuberger A, Sobolevsky AI. Molecular pharmacology of the onco-TRP channel TRPV6. Channels. 2023;17(1):2266669.
[5] Bowen CV, DeBay D, Ewart HS, et al. In Vivo Detection of Human TRPV6-Rich Tumors with Anti-Cancer Peptides Derived from Soricidin. PLoS ONE. 2013 Mar 15;8(3):e58866.
[6] Yan J, Wang Y, Tong B, et al. Disruption of the gut microbiota induces the LCA/TRPV6 signalling axis, impairing desmosome junctions in vitamin A-deficient rats. Food Res Int. 2025;222:117656.
[7] Xue H, Wang Y, MacCormack TJ, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018;9(17):3196-3207.

Protocol

Cell experiment [1]:

Cell lines

 Caco-2 cells (human epithelial cell line)

Preparation Method

 Caco-2 cells were treated with 10μM SOR-C13 for 30 minutes before treatment with 200μM lithocholic acid for 24 hours, followed by Western blotting, immunofluorescence and transepithelial electrical resistance assay.

Reaction Conditions

 10μM; 30min pretreatment

Applications

 SOR-C13 blocked lithocholic acid-induced inhibition of DSG2 protein expression and inhibited lithocholic acid-induced decrease in transepithelial electrical resistance in Caco-2 cells.
Animal experiment [2]:

Animal models

 Female NOD/SCID mice

Preparation Method

Mice bearing subcutaneous SKOV-3 human ovarian cancer xenografts were intraperitoneally administered SOR-C13 at 400-800mg/kg daily for 12 days, or intermittently on Days 1-3 and 8-10. Tumour volumes were monitored by caliper measurement and mice were assessed for health.

Dosage form

400-800mg/kg; i.p.; daily for 12 days

Applications

SOR-C13 inhibited tumour growth. Daily and intermittent dosing regimens produced indistinguishable tumour growth suppression.
References:
[1] Yan J, Wang Y, Tong B, et al. Disruption of the gut microbiota induces the LCA/TRPV6 signalling axis, impairing desmosome junctions in vitamin A-deficient rats. Food Res Int. 2025;222:117656.
[2] Xue H, Wang Y, MacCormack TJ, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018;9(17):3196-3207.

Product Documents

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
1187852-48-7
Molecular Formula
C72H116N20O19
Molecular Weight
1565.81
Storage
Store at -20°C, away from moisture
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for SOR-C13

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%